Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00125944 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

A Phase 3 study of Healthy and Influenza, sponsored by MedImmune.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target
4
Study locations

NCT00125944 is a Phase 3 study of Healthy and Influenza that has completed, run by MedImmune. The registered enrollment target is 300 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00125944, a Phase 3 study of Healthy and Influenza, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target
4
Study locations

Study Summary

The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.

Conditions Studied

Interventions

  • BIOLOGICAL FluMist

Study Locations (4)

California

  • Radiant Research, San Diego - San Diego

Florida

  • Radiant Research, Daytona Beach - Daytona Beach

Oregon

  • Radiant Research - Portland

Texas

  • Healthcare Discoveries, Inc. - San Antonio

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2005-07
Est. Completion 2006-01
Phase Phase 3

Sponsor

MedImmune

210 total trials

What the Registry Record Tells You About NCT00125944

The ClinicalTrials.gov registry entry for NCT00125944 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which FluMist is the first listed.

NCT00125944 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Oregon.

Frequently Asked Questions

What is clinical trial NCT00125944 about?

NCT00125944 is a clinical study titled "Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults". The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.

What is the current status of trial NCT00125944?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2005-07. Estimated completion is 2006-01.

What conditions does trial NCT00125944 study?

This clinical trial studies the following conditions: Healthy, Influenza.

What interventions are being tested in trial NCT00125944?

The interventions under investigation include: FluMist (BIOLOGICAL).

Who is sponsoring clinical trial NCT00125944?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00125944 being conducted?

This trial has 4 study locations across California, Florida, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.